Gallinat, Alex
Badimon, Lina
Funding for this research was provided by:
Ministerio de Ciencia e InnovaciĆ³n (BES-2017-081378, SAF-2016-76819-R)
Instituto de Salud Carlos III (CIBER-CV)
Article History
Received: 13 April 2022
Accepted: 19 July 2022
First Online: 26 July 2022
Competing interests
: LB received institutional research Grants from AstraZeneca; consultancy fees from Sanofi, Pfizer and Novartis; speaker fees from Sanofi and Novartis. LB is shareholder of the academic spin-off companies GlyCardial Diagnostics S.L. and Ivestatin Therapeutics S.L. All unrelated to the present work. LB is author of the patents EP3219326A1 and WO2017157958A1 regarding the use of DJ-1-derived polypeptides for the treatment of ischemia/reperfusion injury. AG declares no conflict of interest.